Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announces that the Company will draw down SEK 16.5 million under a second tranche of the loan facility totaling SEK 50 million entered into with Fenja Capital II A/S (“Fenja”…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.